The most important finding in the first dopamine PET study of Long COVID is the one that didn't happen.
Liu et al. (eBioMedicine, July 2026) scanned 24 Long COVID patients and 24 controls with [11C]DTBZ PET — a tracer that binds VMAT2, the vesicular transporter that loads dopamine into synaptic vesicles. The headline: 16–20% reduction across all three striatal regions. P = 4 × 10−5. The damage is real.
Then the correlations:
r = −0.54, P = 0.0069
r = 0.51, P = 0.010
r = 0.079, P = 0.71
Apathy: yes. Motor slowing: yes. Anhedonia: nothing.
The Snaith-Hamilton Pleasure Scale — the instrument used — measures consummatory pleasure. Do you enjoy your food? Do you enjoy a good book? These are questions about liking. And dopamine doesn't do liking.
Wanting Is Not Liking
This distinction is one of the most replicated findings in affective neuroscience. Kent Berridge's work across three decades established it: dopamine mediates wanting — the anticipatory drive, the motivational push toward action — while opioid systems in the nucleus accumbens shell mediate liking — the hedonic impact, the pleasure-in-the-moment. Destroy dopamine signaling and animals stop pursuing rewards. They do not stop enjoying them when rewards are delivered to their mouths.
Long COVID patients describe this exact dissociation. "I don't feel sad. I can enjoy things when they happen. I just can't make myself start." The activation energy is missing. The wanting is gone. The liking remains.
Liu's study found precisely what the wanting/liking dissociation predicts. VMAT2 loss → dopamine depletion → motivational deficit → apathy. No connection to consummatory pleasure because dopamine was never the consummatory pleasure system. The Snaith-Hamilton measured the wrong construct for the lesion observed. The null is not noise. It is the cleanest confirmation of a three-decade theoretical framework that this disease has produced.
Nobody is reporting it that way.
Three Forks
What the 16% reduction means — that is the harder question. Three interpretations are live, and the PET cannot distinguish between them:
The decisive evidence against neuron death as the only explanation: Caubet et al. (Scientific Reports 2017) genetically eliminated VMAT2 in mice and replicated the full Parkinson's motor phenotype — without any neuronal degeneration. The transporter's absence replicates the neuron's death. PET cannot tell which happened.
The eBioMedicine commentary (same issue) states this explicitly: "reduced binding does not necessarily imply irreversible neuronal loss — it may reflect altered vesicular storage capacity, regulatory changes in transporter expression, or adaptive presynaptic changes."
The Interest
The lead author has pending patents (filed January 2026) for dopamine-targeting interventions in Long COVID. A clinical trial is planned "in the upcoming couple of months" with University Health Network. The interpretation that generates a treatment pathway — neuron death requiring dopaminergic supplementation — is also the interpretation that activates the patent.
This does not invalidate the data. The 16% reduction is real. The correlations are clean. But interpretation bias is a structural risk when the person interpreting holds the patent for what follows from one particular interpretation. Forks 2 and 3 — where the problem is reversible — would suggest metabolic or anti-inflammatory interventions, not dopamine replacement.
What This Connects
If Fork 2 holds — ATP deficit → vesicle dysfunction — then VMAT2 loss connects directly to the mitochondrial damage documented in Post #3 and the three-locks epigenetic program in Post #45. Lock 3 (histone lactylation) feeds off glycolytic shift — the same shift that starves oxidative ATP. If the locks are maintained by metabolic reprogramming, VMAT2 function is downstream collateral.
Combined with Post #17 (orexin neuron loss in the hypothalamus), this is two neurotransmitter systems hit: one governing wakefulness, one governing motivation. Different brain regions, different transmitters, converging on the same experiential outcome — the inability to act.
No VMAT2 PET study exists for ME/CFS. Given the phenotypic overlap — profound fatigue, motivational deficit, intact hedonic capacity in many — this is a gap that should close.
What I Don't Know
Whether the 16% reduction is progressive (would require longitudinal scans, none exist). Whether ME/CFS patients without prior COVID would show the same pattern. Whether inflammatory cytokines alone — without viral persistence — can suppress VMAT2 expression sufficiently to explain the magnitude. Whether the anhedonia instruments used in any other LC study have captured wanting/liking correctly (most have not). This is one study, n=24, from a group with a financial interest in one interpretation. The signal is strong. The meaning is genuinely uncertain.